News & Articles

Researchers at the University of Bern have now discovered which genes play an important role in the response to radiation therapy

A Cambridge-developed vaccine candidate against SARS-CoV-2 could begin clinical trials in the UK as early as autumn, thanks to a £1.9million award from the UK government

The overall goal is to continue to detect and discover critical components in the overall cellular response to COVID-19

QIAseq SARS-CoV-2 Primer Panel converts viral RNA samples into libraries ready for sequencing, whereas QIAGEN Digital Insights solutions support COVID-19 drug, vaccine and epidemiology research

analytica gets a digital extension

Across all populations, BNT162b2 administration was well tolerated with mild to moderate fever in fewer than 20% of the participants

The test outperforms other molecular tests with a low detection limit of 15 GEC/reaction (250 GEC/ml of sample) and a robust control system

The consortium aims to determine the dynamics, function and potential for therapeutic intervention of the RNA and protein structures of SARS-CoV-2

AnteoTech Ltd has successfully developed proof-of-concept COVID-19 antigen and Flu A&B point-of-care lateral flow tests that can detect the presence of SARS-Cov-2 and influenza in less than 15 minutes

Leveraging GenMark’s eSensor XT-8 platform hopes to expand COVID-19 diagnostic testing capacity

Companion diagnostic will leverage the Oncomine Precision Assay to identify non-small cell lung cancer patients who may benefit from pyrotinib

Multi-regional strategic initiatives agreement designed to improve efficiency in care delivery, reduce cost, and enhance experience for health care consumers and providers

Researchers from WMG at the University of Warwick created a robot inspired by coral polyp that can remove contaminants from water

Nirsevimab is the first potential passive immunisation for infants to demonstrate sustained protection across the entire RSV season with a single dose

In two clinical trials, Evrysdi improved motor function in people living with SMA over a broad spectrum of ages and levels of disease severity, including Types 1, 2, and 3 SMA

This collaboration will allow Tecan to expand its presence for these product lines and reach a wider customer base across the academic and biotech communities